Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13066479 | 0.89 | ALDH1A1 (0.50) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL7111931 | 0.88 | KMT2A (0.50) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL22397693 | 0.82 | MEN1 (0.50) | SIGMAR1SMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL19122068 | 0.82 | KMT2A (0.54) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL8408270 | 0.79 | SLC6A2 (0.48) | SIGMAR1NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL23009723 | 0.79 | SMN1; SMN2 (0.50) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL9315735 | 0.79 | NOTUM (0.51) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL255037 | 0.78 | NOTUM (0.50) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL29057039 | 0.78 | SMN1; SMN2 (0.49) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL18954412 | 0.77 | NOTUM (0.50) | SIGMAR1SMN1; SMN2NOTUMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732158-B2 | Adhesive compositions | HENKEL AG & CO. KGAA (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11732158-B2 | Adhesive compositions | HENKEL AG & CO. KGAA (DE) | 2023-08-22 | — | — | US | disclosed |
| US-10822444-B2 | Reactive resins made from renewable sources | Henkel IP & Holding GmbH (DE) | 2020-11-03 | — | — | US | disclosed |
| US-20200040223-A1 | ADHESIVE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2020-02-06 | — | — | US | disclosed |
| WO-2017066539-A1 | REACTIVE RESINS MADE FROM RENEWABLE SOURCES | Henkel IP & Holding GmbH (DE) | 2017-04-20 | — | — | WO | disclosed |
| EP-2424931-B1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel US IP LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8481659-B2 | Cure accelerators for anaerobic curable compositions | HENKEL CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481659-B2 | Cure accelerators for anaerobic curable compositions | HENKEL CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8362112-B2 | Cure accelerators for anaerobic curable compositions | HENKEL IRELAND LIMITED (IE) | 2013-01-29 | — | — | US | disclosed |
| US-8362112-B2 | Cure accelerators for anaerobic curable compositions | HENKEL IRELAND LIMITED (IE) | 2013-01-29 | — | — | US | disclosed |
| US-20120157641-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | LOCTITE (R&D) LIMITED (IE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157641-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | LOCTITE (R&D) LIMITED (IE) | 2012-06-21 | — | — | US | disclosed |
| US-20120129994-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129994-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010127053-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127055-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157641-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | AHCY, AHCYL1, DNMT3L | SIGMAR1 4206/4885SMN1; SMN2 1184/4885NOTUM 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.